Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.47 |
| ▸ | CDK1 | P06493 | 7/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.47 |
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | GSK3A | P49840 | 5/20 | 0.38 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009275 | 0.83 | DAO (0.37) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL27876354 | 0.79 | CCNB2 (0.33) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL11030452 | 0.78 | MB (0.42) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL2398708 | 0.77 | SRC (0.42) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL21620528 | 0.77 | CDK5 (0.38) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL5893879 | 0.77 | CDK5 (0.44) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL2782735 | 0.77 | GSK3B (0.40) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL22578302 | 0.77 | CDK5 (0.39) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL9214980 | 0.76 | CDK5 (0.47) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL4974211 | 0.74 | CDK5 (0.37) | CDK5CDK5R1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024125668-A1 | HETEROCYCLIC SUBSTITUTED PENTA-SIX-MEMBERED HETEROARYL DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| CN-108290843-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
| WO-2020012357-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012357-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-01-16 | — | — | WO | disclosed |
| EP-3356330-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1244672-B1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6908930-B2 | 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6610688-B2 | For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer | SUGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1244672-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046196-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CSNK1A1, CDK2 | CDK5 29/4885CDK5R1 70/4885CCNB2 758/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | CDK5 49/4885CDK5R1 51/4885CCNB2 15/4885 |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CDK7, CDK2 | CDK5 20/4885CDK5R1 18/4885CCNB2 772/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | CDK5 90/4885CDK5R1 164/4885CCNB2 2510/4885 |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | CDK5 52/4885CDK5R1 78/4885CCNB2 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.